Martine Hoogendoorn1, Talitha L Feenstra2, Yumi Asukai3, Andrew H Briggs4, Ryan N Hansen5, Reiner Leidl6, Nancy Risebrough7, Yevgeniy Samyshkin3, Margarethe Wacker6, Maureen P M H Rutten-van Mölken8. 1. Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: hoogendoorn@imta.eur.nl. 2. Department for Prevention and Health Services Research, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Epidemiology, University Medical Centre Groningen, Groningen, The Netherlands. 3. IMS Health, Economics and Outcomes Research and Real-World Evidence Solutions, London, UK. 4. Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK. 5. Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA. 6. Helmholtz Zentrum München, Institute of Health Economics and Health Care Management, Member of the German Center for Lung Research, Comprehensive Pneumology Center Munich, Neuherberg, Germany. 7. ICON Health Economics, Toronto, Ontario, Canada. 8. Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands.
Abstract
OBJECTIVES: To validate outcomes of presently available chronic obstructive pulmonary disease (COPD) cost-effectiveness models against results of two large COPD trials-the 3-year TOwards a Revolution in COPD Health (TORCH) trial and the 4-year Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial. METHODS: Participating COPD modeling groups simulated the outcomes for the placebo-treated groups of the TORCH and UPLIFT trials using baseline characteristics of the trial populations as input. Groups then simulated treatment effectiveness by using relative reductions in annual decline in lung function and exacerbation frequency observed in the most intensively treated group compared with placebo as input for the models. Main outcomes were (change in) total/severe exacerbations and mortality. Furthermore, the absolute differences in total exacerbations and quality-adjusted life-years (QALYs) were used to approximate the cost per exacerbation avoided and the cost per QALY gained. RESULT: Of the six participating models, three models reported higher total exacerbation rates than observed in the TORCH trial (1.13/patient-year) (models: 1.22-1.48). Four models reported higher rates than observed in the UPLIFT trial (0.85/patient-year) (models: 1.13-1.52). Two models reported higher mortality rates than in the TORCH trial (15.2%) (models: 20.0% and 30.6%) and the UPLIFT trial (16.3%) (models: 24.8% and 36.0%), whereas one model reported lower rates (9.8% and 12.1%, respectively). Simulation of treatment effectiveness showed that the absolute reduction in total exacerbations, the gain in QALYs, and the cost-effectiveness ratios did not differ from the trials, except for one model. CONCLUSIONS: Although most of the participating COPD cost-effectiveness models reported higher total exacerbation rates than observed in the trials, estimates of the absolute treatment effect and cost-effectiveness ratios do not seem different from the trials in most models.
OBJECTIVES: To validate outcomes of presently available chronic obstructive pulmonary disease (COPD) cost-effectiveness models against results of two large COPD trials-the 3-year TOwards a Revolution in COPD Health (TORCH) trial and the 4-year Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial. METHODS: Participating COPD modeling groups simulated the outcomes for the placebo-treated groups of the TORCH and UPLIFT trials using baseline characteristics of the trial populations as input. Groups then simulated treatment effectiveness by using relative reductions in annual decline in lung function and exacerbation frequency observed in the most intensively treated group compared with placebo as input for the models. Main outcomes were (change in) total/severe exacerbations and mortality. Furthermore, the absolute differences in total exacerbations and quality-adjusted life-years (QALYs) were used to approximate the cost per exacerbation avoided and the cost per QALY gained. RESULT: Of the six participating models, three models reported higher total exacerbation rates than observed in the TORCH trial (1.13/patient-year) (models: 1.22-1.48). Four models reported higher rates than observed in the UPLIFT trial (0.85/patient-year) (models: 1.13-1.52). Two models reported higher mortality rates than in the TORCH trial (15.2%) (models: 20.0% and 30.6%) and the UPLIFT trial (16.3%) (models: 24.8% and 36.0%), whereas one model reported lower rates (9.8% and 12.1%, respectively). Simulation of treatment effectiveness showed that the absolute reduction in total exacerbations, the gain in QALYs, and the cost-effectiveness ratios did not differ from the trials, except for one model. CONCLUSIONS: Although most of the participating COPD cost-effectiveness models reported higher total exacerbation rates than observed in the trials, estimates of the absolute treatment effect and cost-effectiveness ratios do not seem different from the trials in most models.
Authors: Matthew Moll; Dandi Qiao; Elizabeth A Regan; Gary M Hunninghake; Barry J Make; Ruth Tal-Singer; Michael J McGeachie; Peter J Castaldi; Raul San Jose Estepar; George R Washko; James M Wells; David LaFon; Matthew Strand; Russell P Bowler; MeiLan K Han; Jorgen Vestbo; Bartolome Celli; Peter Calverley; James Crapo; Edwin K Silverman; Brian D Hobbs; Michael H Cho Journal: Chest Date: 2020-04-27 Impact factor: 9.410
Authors: Afisi S Ismaila; Nancy Risebrough; Melanie Schroeder; Dhvani Shah; Alan Martin; Emma C Goodall; Kerigo Ndirangu; Gerard Criner; Mark Dransfield; David Mg Halpin; MeiLan K Han; David A Lomas Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-11-29
Authors: Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson Journal: Pharmacoeconomics Date: 2019-11 Impact factor: 4.981
Authors: Melanie Schroeder; Nicole Benjamin; Laura Atienza; Chandroday Biswas; Alan Martin; John D Whalen; José Luis Izquierdo Alonso; Juan Antonio Riesco Miranda; Juan José Soler-Cataluña; Alicia Huerta; Afisi S Ismaila Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-07-10
Authors: Seamus Kent; Frauke Becker; Talitha Feenstra; An Tran-Duy; Iryna Schlackow; Michelle Tew; Ping Zhang; Wen Ye; Shi Lizheng; William Herman; Phil McEwan; Wendelin Schramm; Alastair Gray; Jose Leal; Mark Lamotte; Michael Willis; Andrew J Palmer; Philip Clarke Journal: Pharmacoeconomics Date: 2019-11 Impact factor: 4.981
Authors: Soham Shukla; Dhvani Shah; Alan Martin; Nancy A Risebrough; Robyn Kendall; Claus F Vogelmeier; Isabelle Boucot; Lee Tombs; Leif Bjermer; Paul W Jones; Edward Kerwin; Chris Compton; François Maltais; David A Lipson; Afisi S Ismaila Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-11-13
Authors: M T Driessen; J Whalen; B Seewoodharry Buguth; L A Vallejo-Aparicio; I P Naya; Y Asukai; B Alcázar-Navarrete; M Miravitlles; F García-Río; N A Risebrough Journal: Respir Res Date: 2018-11-20